technologygre.blogg.se - Download cholecal

This decision ensures a high strength cholecalciferol preparation will continue to be supplied and funded for people requiring vitamin D supplementation. We understand that the supplier of Cal-d-Forte has notified all pharmacies about this and that stock levels are low. Medsafe provisional consent for Cal-d-Forte expires on 12 February 2016. Cholecalciferol 1.25mg (50,000 iu) tablets (Cal-d-Forte) are currently listed in the Pharmaceutical Schedule in the Alimentary Tract and Metabolism therapeutic group. PHARMAC is actively seeking an oral liquid formulation for listing.Īpproximately 230,000 patients’ access funded cholecalciferol tablets per year. Request for a liquid formulation for paediatric patients who are unable to swallow capsules. Most responses were supportive of the proposal, and the following issues were raised in relation to specific aspects of the proposal: Theme

All consultation responses received by 10 February 2016 were considered in their entirety in making a decision on the proposed changes. We appreciate all of the feedback that we received and acknowledge the time people took to respond.

The STAT dispensing rule applies to dispensings of prescriptions for cholecalciferol.

Prescriptions for Vit.D3 capsules will be limited to subsidy of a maximum of 12 capsules per prescription.

Vit.D3 will have subsidy and delisting protection until 30 June 2017.

Patients who currently use funded Cal-d-Forte tablets will need to switch to the Multichem Vit.D3 capsules.įrom 1 March 2016, Multichem’s Vit.D3 capsules will be listed in Section B and Part II of Section H of the Pharmaceutical Schedule at the following subsidy and price (ex-manufacturer and excluding GST): Chemical.

There will be a cholecalciferol 1.25 mg product listed, fully funded on the Pharmaceutical Schedule, that is Medsafe approved and.

In summary, from 1 March 2016, the effect of the decision is that: The proposal was approved as consulted on.

This was the subject of a consultation letter dated 26 January 2016.

Due to the expiration of Medsafe provisional consent for Cal-d-Forte 1.25 mg (50,000 iu) tablets (supplied by API Consumer Brands), PHARMAC has approved an agreement with Multichem NZ Limited relating to the supply of an alternative cholecalciferol product (Vit.